Early stage NSCLC

79P - Tissue microarray analysis on prognostic value of coexpression of RUNX3 and trimethylated histone H3 lysine 27 in surgically resected patients with stage I non-small cell lung cancer

Authors
  • X. Chen (Fuzhou, China)
  • Y. Deng (Fuzhou, China)
  • Y. Shi (Fuzhou, China)
Speakers
  • X. Chen (Fuzhou, China)

Previous ePoster
199P - Safety meta-analysis of clinical trials delivering TTFields to the upper torso

Next ePosters
180TiP - An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer
No ePoster preview available
15P - TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor
No ePoster preview available
80P - High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC)
169P_PR - Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)
73P - Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries
31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer
36P - Can a BALF profile distinguish hot vs cold lung tumors?
8P - Role of chemokines in resectable non-small cell lung cancer (NSCLC)
129P - Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer
22P - Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors